Avid Bioservices Inc (CDMO)

[pphmtoolong]

Blaming management for the Bavi Sunrise failure is pointless. Blaming the control arm for over-performing is equally pointless. The Bavi-arm Sunrise patients simply did no better than the control arm.

Does the Sunrise failure mean Bavi has not value? No. However, it clearly means Bavi will not receive FDA approval any time soon. Peregrine management needs to swallow this bitter medicine, and they need to change company plans to reflect it.

If Peregrine management doesn't see the need to slash the budget and continue expanding Avid, then they are not as smart as I'd like to think they are.

I don't see how Peregrine can finance the Bavi-immunotherapy campaign to completion without partnering help. However, to get decent partnering terms I believe they need to obtain Phase I or II clinical trial success with Bavi and another immunotherapy. Until that time I hope Peregrine can push the burn rate toward zero.

GLTA, Paul